These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 9210757)

  • 1. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder.
    Sharma RP; Janicak PG; Bissette G; Nemeroff CB
    Am J Psychiatry; 1997 Jul; 154(7):1019-21. PubMed ID: 9210757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients.
    Garver DL; Bissette G; Yao JK; Nemeroff CB
    Am J Psychiatry; 1991 Apr; 148(4):484-8. PubMed ID: 2006695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment.
    Widerlöv E; Lindström LH; Besev G; Manberg PJ; Nemeroff CB; Breese GR; Kizer JS; Prange AJ
    Am J Psychiatry; 1982 Sep; 139(9):1122-6. PubMed ID: 6126127
    [No Abstract]   [Full Text] [Related]  

  • 4. Cerebrospinal fluid somatostatin concentrations in schizophrenia and schizoaffective disorder: the effects of antipsychotic treatment.
    Sharma RP; Bissette G; Janicak P; Davis JM; Nemeroff CB
    Schizophr Res; 1994 Sep; 13(2):173-7. PubMed ID: 7986775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.
    Meltzer HY; Arvanitis L; Bauer D; Rein W;
    Am J Psychiatry; 2004 Jun; 161(6):975-84. PubMed ID: 15169685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurotensin-like immunoreactivity in cerebrospinal fluid of patients with schizophrenia, depression, anorexia nervosa-bulimia, and premenstrual syndrome.
    Nemeroff CB; Bissette G; Widerlov E; Beckmann H; Gerner R; Manberg PJ; Lindstrom L; Prange AJ; Gattaz WF
    J Neuropsychiatry Clin Neurosci; 1989; 1(1):16-20. PubMed ID: 2577718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates.
    Breslin NA; Suddath RL; Bissette G; Nemeroff CB; Lowrimore P; Weinberger DR
    Schizophr Res; 1994 Apr; 12(1):35-41. PubMed ID: 7517175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder.
    Robinson DG; Woerner MG; Alvir JM; Geisler S; Koreen A; Sheitman B; Chakos M; Mayerhoff D; Bilder R; Goldman R; Lieberman JA
    Am J Psychiatry; 1999 Apr; 156(4):544-9. PubMed ID: 10200732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug.
    Skogh E; Sjödin I; Josefsson M; Dahl ML
    J Clin Psychopharmacol; 2011 Feb; 31(1):4-9. PubMed ID: 21192135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF thyrotropin-releasing hormone concentrations differ in patients with schizoaffective disorder from patients with schizophrenia or mood disorders.
    Sharma RP; Martis B; Rosen C; Jonalagadda J; Nemeroff CB; Bissette G
    J Psychiatr Res; 2001; 35(5):287-91. PubMed ID: 11591431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of schizoaffective disorder and schizophrenia with mood symptoms.
    Levinson DF; Umapathy C; Musthaq M
    Am J Psychiatry; 1999 Aug; 156(8):1138-48. PubMed ID: 10450252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders.
    Keck PE; Wilson DR; Strakowski SM; McElroy SL; Kizer DL; Balistreri TM; Holtman HM; DePriest M
    J Clin Psychiatry; 1995 Oct; 56(10):466-70. PubMed ID: 7559373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced CSF neurotensin concentration in drug-free schizophrenic patients.
    Lindström LH; Widerlöv E; Bisette G; Nemeroff C
    Schizophr Res; 1988; 1(1):55-9. PubMed ID: 3154507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs.
    Binder EB; Kinkead B; Owens MJ; Nemeroff CB
    Biol Psychiatry; 2001 Dec; 50(11):856-72. PubMed ID: 11743941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurotensin-dopamine interactions: relevance to schizophrenia and the action of antipsychotic drugs.
    Stowe ZN; Bissette G; Nemeroff CB
    Yakubutsu Seishin Kodo; 1991 Feb; 11(1):49-59. PubMed ID: 1679273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of "atypical" antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder.
    Lerner V; Libov I; Kotler M; Strous RD
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):89-98. PubMed ID: 14687862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of work outcome in neuroleptic-resistant schizophrenia and schizoaffective disorder: cognitive impairment and clozapine treatment.
    Kaneda Y; Jayathilak K; Meltzer H
    Psychiatry Res; 2010 Jun; 178(1):57-62. PubMed ID: 20452677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of switching from oral to LAI antipsychotic treatment on subjective experience of schizophrenic and schizoaffective patients: Preliminary results.
    Pietrini F; Spadafora M; Talamba GA; Godini L; Lelli L; Arcabasso S; Manetti M; Ballerini A
    Int J Psychiatry Clin Pract; 2015 Jun; 19(2):106-13. PubMed ID: 25410156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.